Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.035 USD | -3.27% | -7.90% | -25.25% |
05-09 | Transcript : Bluebird bio, Inc., Q1 2024 Earnings Call, May 09, 2024 | |
05-06 | Bluebird Bio, Inc. Announces Completion of First Cell Collection for LYFGENIA Gene Therapy | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-25.25% | 206M | |
+7.72% | 113B | |
+10.94% | 106B | |
+0.41% | 22.27B | |
-11.91% | 22.22B | |
-5.99% | 19.43B | |
-37.36% | 17.87B | |
-5.57% | 17.24B | |
+6.72% | 14.29B | |
+35.67% | 12.52B |
- Stock Market
- Equities
- BLUE Stock
- News bluebird bio, Inc.
- Morgan Stanley Upgrades Bluebird Bio to Equalweight From Underweight, Boosts Price Target to $7 From $3